Loading...

OKYO Pharma Limited

OKYO.L•LSE
Healthcare
Biotechnology
£1.40
£-0.45(-24.32%)

OKYO Pharma Limited (OKYO.L) Company Profile & Overview

Explore OKYO Pharma Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

OKYO Pharma Limited (OKYO.L) Company Profile & Overview

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

SectorHealthcare
IndustryBiotechnology
CEOGary S. Jacob

Contact Information

https://www.okyopharma.com
44 20 7495 2379
55 Park Lane, London, W1K 1NA

Company Facts

7 Employees
IPO DateJul 17, 2018
CountryGB

Frequently Asked Questions

;